Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

Q1 2026 Results: Sartorius AG Shifts to Higher EPS Growth & Solid Revenue Gains

Explore Sartorius AG’s Q1 2026 results: modest revenue rise, strong EPS growth, and robust bioprocess and lab‑instrument performance—key insights for investors and pharma stakeholders.

Dr. Sarah Winters

26/04/2026, 22:11

4 minutes to read

New Oral Semaglutide Data Boost Novo Nordisk Shares, Strengthen Medicare Access and Market Strategy

Novo Nordisk shares rise as new oral semaglutide data show equal efficacy to injections, with Medicare GLP‑1 Bridge program and price cuts boosting patient access and adherence.

Dr. Sarah Winters

26/04/2026, 21:12

3 minutes to read

Danaher Surges Earnings, Reverses Bioprocessing Decline & Seeks $10B Masimo Acquisition

Danaher’s EPS surprise, bioprocessing rebound, and $10 B Masimo takeover show a pivot to integrated life‑science solutions—boosting orders, consumables, and diagnostic reach.

Dr. Sarah Winters

26/04/2026, 20:22

3 minutes to read

Intuitive Surgical Q1 2026: Robust Revenue, Rising Recurring Growth & AI Advancements Drive Future Value

Intuitive Surgical Q1 2026 earnings show strong revenue growth, expanding recurring streams, AI‑enhanced da Vinci 5 adoption and a bullish analyst outlook.

Dr. Sarah Winters

26/04/2026, 07:57

5 minutes to read

Why Mettler‑Toledo Is a Smart Value Pick for Long‑Term Investors

Discover why Mettler‑Toledo (METL) is a value‑oriented investment with 200%+ 10‑year gains, strong earnings, low volatility, and a recent 1.5% dip that could be a buying opportunity for long‑term investors.

Dr. Sarah Winters

26/04/2026, 07:37

3 minutes to read

Merck KGaA Set to Announce 2025 Financial Outlook, Dividend and Strategic Partnerships – What Investors Should Expect

Merck KGaA’s April events—AGM, dividend announcement, and partnership updates—shape investor outlook, revealing fiscal guidance, dividend strategy, and pipeline priorities for future growth.

Dr. Sarah Winters

26/04/2026, 02:22

2 minutes to read

FMC’s Stable German Market Performance & New Global Symvess Deal Boosts Investor Confidence

FMC’s April 2026 market update shows steady stock movement, a new Symvess licensing deal with Humacyte, and insights for investors and clinicians on future growth.

Dr. Sarah Winters

25/04/2026, 23:33

3 minutes to read

Kyowa Kirin Launches Phase 2 Japanese Trial of Ziftomenib for NPM1‑Mutated AML

Phase 2 Japanese trial of ziftomenib (KOMZIFTI) targets relapsed or refractory NPM1‑mutated AML, assessing oral menin‑inhibitor safety, remission rates, and global approval prospects.

Dr. Sarah Winters

25/04/2026, 16:27

3 minutes to read

Merck’s Shares Hit Temporary XETR Trading Halt, ETFs and Reshoring Talks Continue

Merck’s MRK stock faces a temporary XETR outage, halting German trading—investors should monitor the pause and its impact on dividend‑focused ETFs.

Dr. Sarah Winters

25/04/2026, 08:20

3 minutes to read

German DAX Briefly Declines, Infineon Leads Gains Amid Cautious Investor Sentiment

German equity indices slipped slightly; DAX and LUS‑DAX hovered around 24,180. Infineon surged 6%, while Porsche’s low P/E and VW’s dividend lure investors.

Dr. Sarah Winters

25/04/2026, 04:52

2 minutes to read

Newer articles Older articles